Search tips
Search criteria 


Logo of cviJournal InfoAuthorsReviewersSubscribersPermissionsJournals.ASM.orgJournal
Clin Vaccine Immunol. 2010 March; 17(3): 481–484.
Published online 2009 December 30. doi:  10.1128/CVI.00398-09
PMCID: PMC2837972

High Seroprevalence of Neutralizing Capacity against Human Metapneumovirus in All Age Groups Studied in Bonn, Germany[down-pointing small open triangle]


Human metapneumovirus (hMPV) infections occur frequently despite high rates of perpetual seroprevalence for all age groups. Analyses of ~2,000 archived, randomly selected serum samples demonstrated that neutralizing capacities remain high, with a minor decrease for individuals over 69 years of age, leading to the hypothesis that reinfections occur because humoral immune responses play minor roles in the clearance of hMPV infections.

The human metapneumovirus (hMPV) was first isolated in 2001 from children hospitalized with acute respiratory infections (ARIs) (18). hMPV belongs to the Paramyxoviridae family and is one of the major causes of upper and lower ARIs. By the age of five, nearly every child has been infected with hMPV (18). Since hMPV was first described, it has been reported from all over the world, with prevalences of infection ranging from 3.9 to 43% (12, 13). hMPV seems to have a seasonal distribution, like respiratory syncytial virus (RSV) and influenza virus. Infections occur mainly during the winter months (2, 14, 20). Up to now, two genotypes (A and B), each with two subgroups (A1 and A2 and B1 and B2, respectively), have been identified (11), but it is not known if the two genotypes represent two serotypes and if they lead to variations in the severity of clinical symptoms (19). Symptoms associated with a hMPV infection range from mild infections of the upper respiratory tract to severe lower respiratory tract infections like bronchiolitis and pneumonia. Wheezing, coughing, fever, and dyspnea are frequently observed (2, 9, 18). More-severe hMPV infections primarily affect infants and children, while otherwise healthy adults suffer solely from influenza-like illnesses. However, immunocompromised adults show exacerbated courses of asthma and chronic obstructive pulmonary diseases (8, 10, 21). For the elderly, only a few studies have been released, but it has been stated that hMPV infections often lead to hospitalizations and are associated with high mortality in the elderly (3-5). The aim of the present study was to analyze patient sera for the ability to neutralize hMPV and to investigate whether there are any differences among the different age groups.

Serum samples from a total of 2,000 patient were randomly collected from the archives of the Institute of Virology of the University Hospital Bonn (which includes a large trauma center for the geographic area and a large obstetrics unit, resulting in many patients in the 20- to 50-year-old age range) and screened for neutralizing capacity, using the XTT-based neutralization test described previously (17).

In brief, 5 × 104 genome equivalents (geq) of hMPV cells in 50 μl of Dulbecco's modified Eagle's medium (DMEM) or 50 μl of DMEM without the virus was applied to the wells of a 96-well plate (Nunc, Karlsruhe, Germany). Afterward, 25 μl of sera was added to each well. Finally, 5 × 104 HepG2 cells in 125 μl of medium were added to each well and preincubated for 30 min. The DMEM formulation was clear DMEM with 4.5 g liter−1 glucose, 3% (vol/vol) fetal calf serum (FCS), 1% (vol/vol) 100× penicillin-streptomycin mixture (10,000 U/ml of penicillin and 10 mg/ml of streptomycin), 1% nonessential amino acids, 1% l-glutamine, and 1% sodium pyruvate (all from PAA, Austria).

The cells were incubated for 7 days at 33.4°C and 5.0% CO2. The confluence and morphology of the cells were controlled daily under an inverse microscope. At day 7, 150 μl of supernatant was removed from each well and discarded. The prewarmed (37°C) XTT test kit solutions were mixed by pipetting the coupling reagent into the yellow tetrazolium salt. Fifty microliters of the solution was added to each well, and the plate was incubated for 1 h at 33.4°C and 5.0% CO2 before extinction was measured at 456 nm, with 650 nm as the reference measurement, in a 96-well plate reader. For additional verification of the results, cells were counterstained with crystal violet. To investigate the neutralizing capacity of the tested patients' sera, the results of the XTT test of the cells infected with hMPV and treated with patients' sera were compared to a reference dilution series and the results for the corresponding noninfected cells. The optical density (OD) value quotients for the infected and corresponding noninfected cells were calculated. A value less than 1 indicated that the sera had a neutralizing effect on the virus.

For calibration purposes and as a quality control for each test, serial virus dilutions were run in parallel on each plate to ensure that the virus concentration in the inoculum was reciprocal to cell viability, as previously shown (17). As expected, the absorption rate increased with decreasing virus concentrations (Fig. (Fig.1a).1a). A reduction in half of the virus concentration was comparable to an increase in OD of approximately 0.04.

FIG. 1.
(a) Dilution series were performed for quality control. Cells were infected with decreasing amounts of hMPV and incubated for 7 days before an XTT test was performed. Data are given as means ± standard errors of the means (SEMs). (b) Evaluation ...

In total, 2,000 serum samples were initially included in the study. The sera were collected routinely as retained samples and archived for up to 10 years. Collection and archiving of the sera were in concordance with a vote by the local ethical committee. The serum samples were randomly selected and represent a cross section of the patient cohort admitted to our hospital during the last 10 years and reflect the demographic distribution of patients admitted to our hospital.

Of the 2,000 serum samples tested, 49 were toxic per se for the cultured cells and could not be used for further evaluations. Of the remaining 1,951 serum samples, 1,879 (96.21%) showed neutralizing effects (Table (Table1).1). The majority of the negative serum samples were from cohorts of patients who were 0 to ≤2, 60 to 69, and 70 to 79 years old. The sera of the group of patients who were >2 to 9 years old showed the least virus neutralization capacity. Neutralizing capacity increased in patients 10 to 29 years old before it reached a plateau. On average, the neutralizing effect was ~10% higher for patients 29 to 69 years old than for patients 0 to ≤2 years old and ~20% higher than for patients >2 to 9 years old. Starting with patients 70 to 79 years old, a trend of decreasing neutralizing ability of the sera was seen (Fig. (Fig.1b).1b). Admittedly, the standard deviation for the older-patient groups is very high due to the small group size, but the results indicate that it may be worth conducting more-specific surveys on the elderly concerning neutralization potency.

Age distribution of patients and number of samples per group that tested positive or negative for neutralizing abilitya

The results correlate with previous seroprevalence studies, which report that 90 to 100% of children 5 to 10 years old have experienced infection with hMPV (7, 16, 18, 22). In the present study, the 0- to ≤2-year-old group seemed to have a higher rate of seroprevalence than the >2- to 9-year-old group. This finding may be due to different factors. First of all, the neutralization test does not determine the total amount of hMPV-specific antibodies in a patient's serum; instead, it identifies the ability of a patient's serum to neutralize the virus. The sera of very young infants may contain antibodies obtained from breast milk; it can also be assumed that as the sera used in our study were obtained from children hospitalized for different causes, the sera contained immunoglobulins or drugs administered for therapeutical reasons. Although this hypothesis should be tested further with a larger number of patients in the >2- to 9-year-old age group, our study supports it, as we observed a tendency for the neutralization capacity of sera to increase up to the age of 12 months, decrease from 1 to 2 years of age, and then increase gradually up to adulthood (Fig. (Fig.1b1b).

Younger children, as well as the elderly, often develop severe courses of diseases after an infection with hMPV, which is surely connected with the efficiency of the immune system, as immunocompromised patients also suffer from severe etiopathologies.

The adaptive immune system develops permanently during aging. Therefore, young children have not yet established a mature immune response, as they have not been in contact with as many pathogens as adults have. After the maturation of the immune system, pathogens can be eliminated faster and more easily. Later in life, in the elderly population, the immune system suffers from a change in immunity, termed immunosenescence. The term immunosenescence encompasses all processes leading to a dysfunctional immunity in the elderly. It is mainly characterized by failures of the T-lymphocyte system (15). These failures manifest in a dislocation of the ratio between cells previously exposed to an antigen and cells able to recognize and attack new antigens to the benefit of the antigen to which the first exposure was experienced (15).

Neutralizing antibodies seem to be present in all age groups, as the results of the present study indicate, so it may be the efficacy of the antibodies or the contribution of such neutralizing antibodies to protection against hMPV reinfections that changes during the human life span. A study in a BALB/c mouse model showed that infectious hMPV persists in the lungs despite the presence of neutralizing antibodies (1). Moreover, antibody depletion of T cells and natural killer cells results in higher titers of hMPV in the lung, further supporting the theory that the immune system in the elderly becomes malfunctional.

In another BALB/c mouse study, 8- and 18-month-old mice were infected with hMPV. The aged mice showed a higher level of clinical severity, and the production of virus-specific antibodies and neutralizing antibodies was lower in the aged mice than in the young mice (6). Although this latter observation was for a primary infection in aged mice, it may also be indicative of the situation in the elderly, in which a reinfection is more likely. In concert with the results presented here, this observation leads to the hypothesis that it is the host's T-cell response that clears hMPV infection rather than the neutralizing humoral response; immunosenescence seems to be characterized not by a lack of protective antibodies but by an insufficient cellular response.


[down-pointing small open triangle]Published ahead of print on 30 December 2009.


1. Alvarez, R., K. S. Harrod, W. J. Shieh, S. Zaki, and R. A. Tripp. 2004. Human metapneumovirus persists in BALB/c mice despite the presence of neutralizing antibodies. J. Virol. 78:14003-14011. [PMC free article] [PubMed]
2. Bastien, N., D. Ward, C. P. Van, K. Brandt, S. H. Lee, G. McNabb, B. Klisko, E. Chan, and Y. Li. 2003. Human metapneumovirus infection in the Canadian population. J. Clin. Microbiol. 41:4642-4646. [PMC free article] [PubMed]
3. Boivin, G., Y. Abed, G. Pelletier, L. Ruel, D. Moisan, S. Cote, T. C. Peret, D. D. Erdman, and L. J. Anderson. 2002. Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J. Infect. Dis. 186:1330-1334. [PubMed]
4. Boivin, G., S. G. De, M. E. Hamelin, S. Cote, M. Argouin, G. Tremblay, R. Maranda-Aubut, C. Sauvageau, M. Ouakki, N. Boulianne, and C. Couture. 2007. An outbreak of severe respiratory tract infection due to human metapneumovirus in a long-term care facility. Clin. Infect. Dis. 44:1152-1158. [PubMed]
5. Chiu, C. Y., A. A. Alizadeh, S. Rouskin, J. D. Merker, E. Yeh, S. Yagi, D. Schnurr, B. K. Patterson, D. Ganem, and J. L. DeRisi. 2007. Diagnosis of a critical respiratory illness caused by human metapneumovirus by use of a pan-virus microarray. J. Clin. Microbiol. 45:2340-2343. [PMC free article] [PubMed]
6. Darniot, M., C. Pitoiset, T. Petrella, S. Aho, P. Pothier, and C. Manoha. 2009. Age-associated aggravation of clinical disease after primary metapneumovirus infection of BALB/c mice. J. Virol. 83:3323-3332. [PMC free article] [PubMed]
7. Ebihara, T., R. Endo, H. Kikuta, N. Ishiguro, H. Ishiko, and K. Kobayashi. 2004. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J. Med. Virol. 72:304-306. [PubMed]
8. Englund, J. A., M. Boeckh, J. Kuypers, W. G. Nichols, R. C. Hackman, R. A. Morrow, D. N. Fredricks, and L. Corey. 2006. Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients. Ann. Intern. Med. 144:344-349. [PubMed]
9. Esper, F., D. Boucher, C. Weibel, R. A. Martinello, and J. S. Kahn. 2003. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics 111:1407-1410. [PubMed]
10. Kamble, R. T., C. Bollard, G. Demmler, P. R. LaSala, and G. Carrum. 2007. Human metapneumovirus infection in a hematopoietic transplant recipient. Bone Marrow Transplant. 40:699-700. [PubMed]
11. Mackay, I. M., S. Bialasiewicz, Z. Waliuzzaman, G. R. Chidlow, D. C. Fegredo, S. Laingam, P. Adamson, G. B. Harnett, W. Rawlinson, M. D. Nissen, and T. P. Sloots. 2004. Use of the P gene to genotype human metapneumovirus identifies 4 viral subtypes. J. Infect. Dis. 190:1913-1918. [PubMed]
12. Maggi, F., M. Pifferi, M. Vatteroni, C. Fornai, E. Tempestini, S. Anzilotti, L. Lanini, E. Andreoli, V. Ragazzo, M. Pistello, S. Specter, and M. Bendinelli. 2003. Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy. J. Clin. Microbiol. 41:2987-2991. [PMC free article] [PubMed]
13. Mullins, J. A., D. D. Erdman, G. A. Weinberg, K. Edwards, C. B. Hall, F. J. Walker, M. Iwane, and L. J. Anderson. 2004. Human metapneumovirus infection among children hospitalized with acute respiratory illness. Emerg. Infect. Dis. 10:700-705. [PubMed]
14. Pabbaraju, K., S. Wong, T. McMillan, B. E. Lee, and J. D. Fox. 2007. Diagnosis and epidemiological studies of human metapneumovirus using real-time PCR. J. Clin. Virol. 40:186-192. [PubMed]
15. Pawelec, G., S. Koch, C. Franceschi, and A. Wikby. 2006. Human immunosenescence: does it have an infectious component? Ann. N. Y. Acad. Sci. 1067:56-65. [PubMed]
16. Peret, T. C., G. Boivin, Y. Li, M. Couillard, C. Humphrey, A. D. Osterhaus, D. D. Erdman, and L. J. Anderson. 2002. Characterization of human metapneumoviruses isolated from patients in North America. J. Infect. Dis. 185:1660-1663. [PubMed]
17. Schildgen, V., J. Lüsebrink, V. Ditt, R. Tillmann, A. Simon, A. Müller, and O. Schildgen. 2010. Human HepG2 cells support respiratory syncytial virus and human metapneumovirus replication. J. Virol. Methods 163:74-81. [PubMed]
18. van den Hoogen, B. G., J. C. de Jong, J. Groen, T. Kuiken, R. de Groot, R. A. Fouchier, and A. D. Osterhaus. 2001. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat. Med. 7:719-724. [PubMed]
19. van den Hoogen, B. G., S. Herfst, L. Sprong, P. A. Cane, E. Forleo-Neto, R. L. de Swart, A. D. Osterhaus, and R. A. Fouchier. 2004. Antigenic and genetic variability of human metapneumoviruses. Emerg. Infect. Dis. 10:658-666. [PubMed]
20. van den Hoogen, B. G., D. M. Osterhaus, and R. A. Fouchier. 2004. Clinical impact and diagnosis of human metapneumovirus infection. Pediatr. Infect. Dis. J. 23:S25-S32. [PubMed]
21. Williams, J. V., J. E. Crowe, Jr., R. Enriquez, P. Minton, R. S. Peebles, Jr., R. G. Hamilton, S. Higgins, M. Griffin, and T. V. Hartert. 2005. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J. Infect. Dis. 192:1149-1153. [PMC free article] [PubMed]
22. Wolf, D. G., Z. Zakay-Rones, A. Fadeela, D. Greenberg, and R. Dagan. 2003. High seroprevalence of human metapneumovirus among young children in Israel. J. Infect. Dis. 188:1865-1867. [PubMed]

Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of American Society for Microbiology (ASM)